Idioma:

Cachexia: Pathophysiology and Ghrelin Liposomes for Nose-to-Brain Delivery

T de Barros, Cecilia ; Rios, Alessandra C ; Alves, Thaís F R ; Batain, Fernando ; Crescencio, Kessi M M ; Lopes, Laura J ; Zielińska, Aleksandra ; Severino, Patricia ; G Mazzola, Priscila ; Souto, Eliana B ; Chaud, Marco V

International journal of molecular sciences, 2020-08, Vol.21 (17), p.5974 [Periódico revisado por pares]

Switzerland: MDPI AG

Texto completo disponível

Citações Citado por

Enviar para

Título:
Cachexia: Pathophysiology and Ghrelin Liposomes for Nose-to-Brain Delivery
Autor: T de Barros, Cecilia ; Rios, Alessandra C ; Alves, Thaís F R ; Batain, Fernando ; Crescencio, Kessi M M ; Lopes, Laura J ; Zielińska, Aleksandra ; Severino, Patricia ; G Mazzola, Priscila ; Souto, Eliana B ; Chaud, Marco V
Assuntos: Administration, Intranasal ; Animals ; Apoptosis ; Appetite ; Bioavailability ; Blood-brain barrier ; Blood-Brain Barrier - metabolism ; Cachexia ; Cachexia - drug therapy ; Cachexia - etiology ; Catabolism ; Catecholamines ; Central nervous system ; Chronic illnesses ; Chronic obstructive pulmonary disease ; Cytokines ; Drug delivery systems ; Enzymes ; Ghrelin ; Ghrelin - administration & dosage ; Ghrelin - metabolism ; Ghrelin - therapeutic use ; Humans ; Infectious diseases ; Inflammation ; Liposomes ; Liposomes - metabolism ; Low income groups ; Metabolism ; Mortality ; Muscles ; Musculoskeletal system ; Nervous system ; Nose ; nose-to-brain ; Patients ; Peptides ; Physiological effects ; Public health ; Quality of life ; Review ; Sepsis ; Tumor necrosis factor-TNF
É parte de: International journal of molecular sciences, 2020-08, Vol.21 (17), p.5974
Notas: ObjectType-Article-2
SourceType-Scholarly Journals-1
ObjectType-Feature-3
content type line 23
ObjectType-Review-1
Descrição: Cachexia, a severe multifactorial condition that is underestimated and unrecognized in patients, is characterized by continuous muscle mass loss that leads to progressive functional impairment, while nutritional support cannot completely reverse this clinical condition. There is a strong need for more effective and targeted therapies for cachexia patients. There is a need for drugs that act on cachexia as a distinct and treatable condition to prevent or reverse excess catabolism and inflammation. Due to ghrelin properties, it has been studied in the cachexia and other treatments in a growing number of works. However, in the body, exogenous ghrelin is subject to very rapid degradation. In this context, the intranasal release of ghrelin-loaded liposomes to cross the blood-brain barrier and the release of the drug into the central nervous system may be a promising alternative to improve its bioavailability. The administration of nose-to-brain liposomes for the management of cachexia was addressed only in a limited number of published works. This review focuses on the discussion of the pathophysiology of cachexia, synthesis and physiological effects of ghrelin and the potential treatment of the diseased using ghrelin-loaded liposomes through the nose-to-brain route.
Editor: Switzerland: MDPI AG
Idioma: Inglês

Links

View this record in MEDLINE/PubMed

Voltar para lista de resultados

Realização: Logos de Redes Sociais:

Cachexia: Pathophysiology and Ghrelin Liposomes for Nose-to-Brain Delivery

T de Barros, Cecilia ; Rios, Alessandra C ; Alves, Thaís F R ; Batain, Fernando ; Crescencio, Kessi M M ; Lopes, Laura J ; Zielińska, Aleksandra ; Severino, Patricia ; G Mazzola, Priscila ; Souto, Eliana B ; Chaud, Marco V

Switzerland: MDPI AG

Buscando em bases de dados remotas. Favor aguardar.